On March 14, 2022, Daniel J. Abdun-Nabi notified REGENXBIO Inc. that he will not stand for re-election as a director of the Company at the end of his current term, which expires at the Company's 2022 annual meeting of stockholders.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.09 USD | +4.21% | -4.33% | -10.08% |
May. 09 | UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating | MT |
May. 08 | Transcript : REGENXBIO Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.08% | 761M | |
+5.07% | 109B | |
+11.65% | 105B | |
+0.03% | 22.25B | |
-12.18% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.78% | 16.85B | |
+4.93% | 13.76B | |
+35.17% | 12.46B |
- Stock Market
- Equities
- RGNX Stock
- News REGENXBIO Inc.
- Daniel J. Abdun-Nabi Notifies REGENXBIO Inc. Will Not Stand for Re-Election